Reponex’s strategy is in a cost-effective way to reposition, reroute and recombine drugs that, in parallel and effectively, affect various aspects of the disease to achieve a potent treatment effect.
This means essentially finding a new use for an established drug. Characteristically, this entails using the drug for a different indication (i.e. for treating another disease) than it was initially developed for, with the advantage of opening up a new market while saving on the preclinical and clinical phase I developing costs. Simple rerouting of this type has become a standard strategy employed by established pharmaceutical companies to extend their pipeline.
This means changing the route of administering the drug to a new one that is appropriate for the new indication. Essentially it means that Reponex reformulates the active pharmaceutical ingredients to make them suitable for local administration to the site where it needs to act, avoiding conventional systemic administration e.g. by intravenous or subcutaneous injection. This dramatically improves the efficacy of the drug, which reaches its site of action at high concentration, while correspondingly reducing or eliminating any systemic adverse reactions to drugs that penetrate poorly or not at all from the site of action to the systemic circulation.
This means combining different drugs that act on different aspects of the disease pathology to achieve an additive or even synergistic effect. At the same time, it is convenient for both the patient and the clinician not to have to apply several different medications at once to treat a single condition, but to use the preparation that has been developed to provide the best generally applicable combination. This principle is particularly well known in the drug combinations used to treat high blood pressure.